AbbVie has agreed to acquire Apogee Therapeutics for approximately $10.9 billion, expanding its immunology pipeline and respiratory disease portfolio. The transaction is expected to close in the third quarter of 2026.
Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, according to a June 22 company news release. The boards of directors of both companies unanimously approved the transaction.
The acquisition adds several clinical-stage assets focused on inflammatory and immunological diseases, including Apogee’s lead candidate, zumilokibart (APG777), a monoclonal antibody targeting IL-13 that is being developed for patients with atopic dermatitis.
Apogee’s pipeline also includes APG273, a combination therapy targeting IL-13 and thymic stromal lymphopoietin that is being developed for asthma. In a phase 2 trial, approximately two-thirds of patients receiving zumilokibart achieved significant skin clearance at 16 weeks.
